request. PZM 08/13 20:05 Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program BFW 08/13 20:24 "AVALANCHE WON'T START A PHASE 2B TRIAL OF AVA-101 FOR WET AMD BN 08/13 20:24 *AVALANCHE WONT START A PHASE 26 TRIAL OF AVA-101 FOR WET AMD BN 08/13 20:24 *AVALANCHE WONT STARTA PHASE 2B TRIAL OF AVA-101 FOR WET AMD BN 08/13 20:24 *AVALANCHE WON'T INITIATE PHASE 26 TRIAL BN 08/13 20:19 *AVALANCHE BIOTECHNOLOGIES 2Q REV $0.2M, EST. $0.4M BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, 2Q LOSS/SHR 38C BN 08/13 20:05 *AVALANCHE BIOTECHNOLOGIES, REPORTS 2Q'15 FINANCIAL RESULTS, Avalanche Bio Falls After Scrapping Plans for Ph.2b Study in 2H 2015-08-13 20:35:05.499 GMT By Jeremy R. Cooke (Bloomberg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA-101 for potential treatment of wet age-related macular degeneration. AAVL down 20% post-mkt after 112k shrs traded. * AAVL instead will run added preclinical studies to investigate optimal dose and delivery of AVA-101 and AVA-201 vs standard of care anti-VEGF protein therapy to select best gene therapy product candidate for wet AMD * AAVL says it's on track to complete candidate selection for AVA-201 by end of 2015 * Cash/equivalents $279.6m as of June 30 vs $159.4m at end of 2014; AAVL doesn't see burn rate recognized over past two quarters changing "substantially" over next 18 months * 2Q rev. $0.2m, est. $0.4m * 2Q loss/shr 38c, est. loss 37c * NOTE: AAVL shrs were down 74% year through today's close * June 15, Avalanche Bio Falls as Drug Tied to Retinal Thickening in AMD; Link * June 16, AVALANCHE STREET WRAP: Analyst Ratings Cut on Controversial Data; Link Statement: Link Link to Company News:(AAVL US <Equity> CN <GO>) For Related News and Information: First Word scrolling panel: (FIRST<GO>) First Word newswire: {NH BFW<GO>} To contact the e